Invention Application
- Patent Title: Macrocyclic MCL-1 Inhibitors and Methods of Use
-
Application No.: US16575114Application Date: 2019-09-18
-
Publication No.: US20200010480A1Publication Date: 2020-01-09
- Inventor: Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
- Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Main IPC: C07D498/18
- IPC: C07D498/18 ; A61P35/00 ; C07D519/00 ; C07D495/18 ; C07D495/16
Abstract:
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
Information query
